1. bookVolumen 66 (2019): Edición 2 (November 2019)
Detalles de la revista
License
Formato
Revista
eISSN
2453-6725
Primera edición
25 Nov 2011
Calendario de la edición
2 veces al año
Idiomas
Inglés
Acceso abierto

Antidepressant effects of valproic acid in an animal model of depression

Publicado en línea: 28 Jan 2020
Volumen & Edición: Volumen 66 (2019) - Edición 2 (November 2019)
Páginas: 1 - 3
Recibido: 18 May 2019
Aceptado: 22 May 2019
Detalles de la revista
License
Formato
Revista
eISSN
2453-6725
Primera edición
25 Nov 2011
Calendario de la edición
2 veces al año
Idiomas
Inglés

[1] Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn Mem. 2008; 15(1):39-45.10.1101/lm.801108 Search in Google Scholar

[2] Heinrichs SC, Leite-Morris KA, Rasmusson AM, Kaplan GB. Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci Lett. 2013; 552:108-13.10.1016/j.neulet.2013.07.035 Search in Google Scholar

[3] Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav. 2008; 54(1):90-7.10.1016/j.yhbeh.2008.02.004 Search in Google Scholar

[4] Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 82:332-338.10.1016/j.pnpbp.2017.07.008 Search in Google Scholar

[5] Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol. 2012;15(2):247-65.10.1017/S1461145711000368 Search in Google Scholar

[6] Lima IVA, Almeida-Santos AF, Ferreira-Vieira TH, Aguiar DC, Ribeiro FM, Campos AC, de Oliveira ACP. Antidepressant-like effect of valproic acid-Possible involvement of PI3K/Akt mTOR pathway. Behav Brain Res. 2017; 329:166-171.10.1016/j.bbr.2017.04.015 Search in Google Scholar

[7] Pistovcakova J, Dostalek M, Sulcova A, Jezova D. Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression. Pharmacopsychiatry. 2008; 41(2):54-9.10.1055/s-2007-993212 Search in Google Scholar

[8] Qiu HM, Yang JX, Jiang XH, Hu XY, Liu D, Zhou QX. Enhancing tyrosine hydroxylase and tryptophan hydroxylase expression and improving oxidative stress involved in the antidepressant effect of sodium valproate on rats undergoing chronic unpredicted stress. Neuroreport. 2015; 26(18):1145-50.10.1097/WNR.0000000000000482 Search in Google Scholar

[9] Qiu HM, Yang JX, Liu D, Fei HZ, Hu XY, Zhou QX. Antidepressive effect of sodium valproate involving suppression of corticotropin-releasing factor expression and elevation of BDNF expression in rats exposed to chronic unpredicted stress. Neuroreport. 2014; 25(4):205-10.10.1097/WNR.0000000000000054 Search in Google Scholar

[10] Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010; 122(1-2):1-9.10.1016/j.jad.2009.10.033 Search in Google Scholar

[11] Buzgoova K, Graban J, Balagova L, Hlavacova N, Jezova D. Brain derived neurotrophic factor expression and DNA methylation in response to subchronic valproic acid and/or aldosterone treatment. Croat Med J. 2019 (in press).10.3325/cmj.2019.60.71 Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo